Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Trial Profile

Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Etravirine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 13 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 02 Jun 2016 Planned End Date changed from 1 Dec 2021 to 1 Dec 2017.
    • 02 Jun 2016 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top